Intralesional Therapy for the Treatment of Keratoacanthoma
April 2019
in “
Dermatologic therapy
”
TLDR Intralesional therapy for keratoacanthoma is effective and has fewer side effects than systemic treatments.
Keratoacanthoma (KA) is a benign epidermal tumor originating from hair follicles, with rare potential to transform into squamous cell carcinoma. While surgical excision is the gold standard treatment, intralesional therapy offers a cosmetically and functionally preferable alternative with similar outcomes and fewer side effects compared to systemic treatments. Methotrexate is the most commonly used intralesional agent, followed by 5-fluorouracil and interferon alpha. Despite its advantages, guidelines for intralesional treatment of KA are not yet established, and histopathological confirmation is recommended to avoid misdiagnosis. The study reviewed the current state of intralesional treatment for KA.
